CAPR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Capricor Therapeutics is facing a case alleging the company and certain executives made false or misleading statements to investors. The report is negative from an investor-relations and governance standpoint, but no financial impact figures (e.g., $ damages or guidance changes) were provided in the text.

Analysis

Capricor Therapeutics is facing a case alleging the company and certain executives made false or misleading statements to investors. The report is negative from an investor-relations and governance standpoint, but no financial impact figures (e.g., $ damages or guidance changes) were provided in the text.